A patient will be taking a 2-week course of medications for a peptic ulcer. The nurse expects that omeprazole will be one of the medications ordered.
The nurse knows that a drug from what other classification of medication would be ordered with the omeprazole?

This question tests clinical recognition of digoxin toxicity, especially in the context of concurrent diuretic use. It requires identifying classic, pathognomonic symptoms of digitalis poisoning, which necessitate immediate nursing intervention to prevent life-threatening cardiac dysrhythmias and associated potential mortality in the clinical setting.

Choice A rationale

Vomiting and visual disturbances, specifically yellow-green halos around lights, are classic signs of digoxin toxicity. Because the patient is also on furosemide, which may induce hypokalemia, the risk for severe arrhythmias is high, requiring urgent clinical assessment.

Choice B rationale

Stomach upset and headache are non-specific symptoms that can occur with many medications. While they should be documented, they are not the specific, hallmark clinical indicators of life-threatening digitalis toxicity that require an emergency level of immediate nursing assessment.

Choice C rationale

Increased urine frequency is the intended therapeutic outcome of furosemide therapy. It indicates that the diuretic is working to reduce fluid overload in the heart failure patient and does not represent an adverse medication event requiring immediate intervention.

Choice D rationale

Night sweats and insomnia are not clinical features associated with digoxin toxicity or furosemide therapy. While they may be indicative of other clinical issues, they do not require the urgent, immediate cardiac assessment that is necessary when assessing for digoxin-related toxicity.

This question evaluates the understanding of parenteral drug administration routes. It requires identifying the pharmacological advantages of avoiding the gastrointestinal tract, specifically how parenteral routes bypass initial hepatic metabolism, thereby ensuring greater drug bioavailability compared to drugs that undergo significant first-pass metabolism.

Choice A rationale

Parenteral drugs are administered via routes like IV or IM, avoiding the stomach entirely. Absorption kinetics are not related to gastric contents, as the medication is delivered directly into the systemic circulation or muscle tissue for uptake.

Choice B rationale

The first-pass effect refers to the metabolic breakdown of oral drugs by the liver before they reach systemic circulation. Parenteral routes, such as intravenous administration, bypass this process entirely, allowing the drug to reach target sites without initial hepatic degradation.

Choice C rationale

Stomach pH only affects the absorption of orally administered drugs that must survive the gastric environment and cross the mucosal lining. Parenteral medications are delivered outside of the digestive tract, so gastric pH has no impact on their bioavailability.

Choice D rationale

Parenteral drugs exert systemic effects by circulating through the bloodstream to reach various target tissues and organs throughout the body. They do not depend on the intestines for their action, as they are not administered via the enteral route.